and activity of quisinostat against .

an opportunistic pathogen, poses severe threats to immunocompromised individuals and fetuses of newly infected pregnant women. The current gold-standard treatment, a combination of pyrimethamine and sulfadiazine, is limited by severe adverse events, necessitating the development of novel therapeutic agents. , a CCK8 assay demonstrated that quisinostat inhibited HeLa cell proliferation in a dose-dependent manner, with a CC of 8.22 nM. Regarding tachyzoites, quisinostat exhibited time-dependent inhibition of extracellular parasite activity and suppressed intracellular parasite proliferation, with an EC of 25.84 pM, and a high selectivity index (SI = 318.11). Quisinostat disrupted the lytic cycle by decreasing invasion rates, inducing G1 cell cycle arrest, reducing replication, and shrinking plaque size. Ultrastructural analysis indicated that quisinostat treatment led to membrane damage, enhanced lactate dehydrogenase (LDH) release, and apoptotic cell death in tachyzoites, whereas no significant change in reactive oxygen species (ROS) levels was detected. Proteome analysis identified 77 upregulated and 205 downregulated proteins, which were enriched in functions associated with protein dephosphorylation and ion transport, as well as pathways, such as non-homologous end-joining. Molecular docking studies revealed a strong interaction between quisinostat and HDAC3. , treatment with quisinostat increased the survival time of mice infected with virulent RH strain. In mice infected with low-virulent ME49 tachyzoites, quisinostat treatment decreased parasite burden in multiple organs and increased the survival to 80%. Taken together, these findings demonstrate that quisinostat has potent anti- activity both and , which offers promise for treatment of human toxoplasmosis.